JNJ
Johnson & Johnson$266.07-0.21 (-0.08%)Prev Close$266.32·MCap$643.64B·P/E30.76·Vol3.09M·Yield0.02%
▲
Buys (12M)
1
$257.7K
▼
Sells (12M)
26
$199.06M
◆
Net Activity
Net Seller
$198.80M
●
Active Insiders
13
last 12 mo
Over the past 12 months, insider activity at Johnson & Johnson (JNJ) has been dominated by selling, with 1 insider purchase totaling $257.7K and 26 insider sales totaling $199.06M. The most recent insider transaction was by Schmid Timothy (officer: EVP, WW Chair, MedTech), who sold $6.19M worth of shares on Sep 4, 2026. Johnson & Johnson operates in the Healthcare sector, within the Drug Manufacturers - General industry, with a market cap of $643.64B.
JNJ Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Schmid Timothy | officer: EVP, WW Chair, MedTech | Sell | 22,527 | $274.74 | $6.19M | 25,447-47% |
| Aug 18, 2026 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | Sell | 15,000 | $263.36 | $3.95M | 194,451 |
| Aug 14, 2026 | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 123,291 | $261.17 | $32.20M | 378,282 |
| Aug 7, 2026 | Forminard Elizabeth | officer: EVP, Chief Legal Officer | Sell | 15,918 | $257.00 | $4.09M | 23,568-40% |
| Aug 7, 2026 | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 48,480 | $258.15 | $12.52M | 282,490 |
| Jul 21, 2026 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | Sell | 23,054 | $251.27 | $5.79M | 23,003-50% |
| Jun 12, 2026 | Wengel Kathryn E | officer: EVP, Chief TO and Risk Officer | Sell | 10,000 | $241.15 | $2.41M | 114,288 |
| Mar 3, 2026 | Decker Robert J | officer: VP Corporate Controller | Sell | 4,075 | $247.87 | $1.01M | 23,682 |
| Feb 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $324.8K | 0 |
| Feb 18, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 7,266 | $244.45 | $1.78M | 0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 54,844 | $243.01 | $13.33M | 0 |
| Feb 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 10,611 | $243.82 | $2.59M | 0 |
| Feb 13, 2026 | Decker Robert J | VP Corporate Controller | Sell | 1,055 | $244.35 | $257.8K | 0 |
| Feb 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | Sell | 36,230 | $244.44 | $8.86M | 0 |
| Feb 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 8,361 | $244.41 | $2.04M | 0 |
| Feb 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Sell | 1,585 | $244.26 | $387.1K | 0 |
| Feb 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 24,910 | $244.33 | $6.09M | 0 |
| Feb 13, 2026 | Swanson James D. | EVP, CIO | Sell | 66,293 | $243.46 | $16.14M | 0 |
| Feb 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 15,717 | $244.43 | $3.84M | 0 |
| Feb 13, 2026 | Wolk Joseph J | Exec VP, CFO | Sell | 107,784 | $243.08 | $26.20M | 0 |
| Jan 28, 2026 | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 200,000 | $221.23 | $44.25M | 79,634-72% |
| Dec 1, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 6,337 | $10.03 | $63.6K | 0 |
| Dec 1, 2025 | MORIKIS JOHN G | Director | Buy | 1,250 | $206.15 | $257.7K | 0 |
| Nov 25, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 2,700 | $10.05 | $27.1K | 0 |
| Nov 14, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 1,000 | $10.00 | $10.0K | 0 |
| Nov 10, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 52,532 | $10.21 | $536.3K | 0 |
| Oct 20, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.19M | 0 |
| Sep 5, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 56,471 | $177.81 | $10.04M | 0 |
| Sep 3, 2025 | Forminard Elizabeth | Executive VP, General Counsel | Sell | 9,570 | $177.20 | $1.70M | 0 |
| Aug 25, 2025 | Duato Joaquin | CEO and Chairman of the Board | Sell | 125,824 | $179.21 | $22.55M | 0 |
| Aug 18, 2025 | Wolk Joseph J | Exec VP, CFO | Sell | 16,820 | $176.91 | $2.98M | 0 |
| Jul 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3.13M | 0 |
| Feb 26, 2025 | Decker Robert J | VP Corporate Controller | Sell | 6,999 | $165.88 | $1.16M | 0 |
| Feb 18, 2025 | Decker Robert J | VP Corporate Controller | Sell | 824 | $156.46 | $128.9K | 0 |
| Feb 18, 2025 | Forminard Elizabeth | Executive VP, General Counsel | Sell | 1,253 | $156.32 | $195.9K | 0 |
| Feb 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 385 | $156.15 | $60.1K | 0 |
| Feb 18, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 2,250 | $156.49 | $352.1K | 0 |
| Feb 18, 2025 | Swanson James D. | EVP, CIO | Sell | 1,740 | $156.54 | $272.4K | 0 |
| Feb 18, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 3,296 | $156.58 | $516.1K | 0 |
| Feb 18, 2025 | Wolk Joseph J | Exec VP, CFO | Sell | 9,080 | $156.58 | $1.42M | 0 |
| Feb 11, 2025 | Duato Joaquin | CEO and Chairman of the Board | Sell | 100,643 | $153.12 | $15.41M | 0 |
| Feb 11, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 47,436 | $153.12 | $7.26M | 0 |
| Feb 11, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 26,076 | $153.12 | $3.99M | 0 |
| Jul 27, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 20,000 | $170.32 | $3.41M | 102,696 |
| Jul 27, 2023 | Hait William | See Remarks | Sell | 14,698 | $172.00 | $2.53M | 87,747 |
| Jun 14, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 12,465 | $160.00 | $1.99M | 65,934 |
| Mar 8, 2023 | Swanson James D. | See Remarks | Sell | 1,061 | $154.66 | $164.1K | 9,215 |
| Dec 15, 2022 | Wolk Joseph J | Exec VP, CFO | Sell | 14,781 | $179.60 | $2.65M | 48,738 |
| Dec 2, 2022 | McEvoy Ashley | EVP, WW Chair, MedTech | Sell | 73,323 | $175.47 | $12.87M | 113,736-39% |
| Nov 23, 2022 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Sell | 76,923 | $176.78 | $13.60M | 126,456-38% |
Showing 1–50 of 55
1 / 2
JNJ Insider Buying Activity
The following table shows recent insider purchases of Johnson & Johnson (JNJ) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | MORIKIS JOHN G | Director | Buy | 1,250 | $206.15 | $257.7K | 0 |
JNJ Insider Selling Activity
The following table shows recent insider sales of Johnson & Johnson (JNJ) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Schmid Timothy | officer: EVP, WW Chair, MedTech | Sell | 22,527 | $274.74 | $6.19M | 25,447-47% |
| Aug 18, 2026 | Taubert Jennifer L | officer: EVP, WWC. Innovative Medicine | Sell | 15,000 | $263.36 | $3.95M | 194,451 |
| Aug 14, 2026 | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 123,291 | $261.17 | $32.20M | 378,282 |
| Aug 7, 2026 | Forminard Elizabeth | officer: EVP, Chief Legal Officer | Sell | 15,918 | $257.00 | $4.09M | 23,568-40% |
| Aug 7, 2026 | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 48,480 | $258.15 | $12.52M | 282,490 |
| Jul 21, 2026 | Broadhurst Vanessa | officer: EVP, Global Corp Affairs | Sell | 23,054 | $251.27 | $5.79M | 23,003-50% |
| Jun 12, 2026 | Wengel Kathryn E | officer: EVP, Chief TO and Risk Officer | Sell | 10,000 | $241.15 | $2.41M | 114,288 |
| Mar 3, 2026 | Decker Robert J | officer: VP Corporate Controller | Sell | 4,075 | $247.87 | $1.01M | 23,682 |
| Feb 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $324.8K | 0 |
| Feb 18, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 7,266 | $244.45 | $1.78M | 0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 54,844 | $243.01 | $13.33M | 0 |
| Feb 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 10,611 | $243.82 | $2.59M | 0 |
| Feb 13, 2026 | Decker Robert J | VP Corporate Controller | Sell | 1,055 | $244.35 | $257.8K | 0 |
| Feb 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | Sell | 36,230 | $244.44 | $8.86M | 0 |
| Feb 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 8,361 | $244.41 | $2.04M | 0 |
| Feb 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Sell | 1,585 | $244.26 | $387.1K | 0 |
| Feb 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 24,910 | $244.33 | $6.09M | 0 |
| Feb 13, 2026 | Swanson James D. | EVP, CIO | Sell | 66,293 | $243.46 | $16.14M | 0 |
| Feb 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 15,717 | $244.43 | $3.84M | 0 |
| Feb 13, 2026 | Wolk Joseph J | Exec VP, CFO | Sell | 107,784 | $243.08 | $26.20M | 0 |
| Jan 28, 2026 | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 200,000 | $221.23 | $44.25M | 79,634-72% |
| Dec 1, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 6,337 | $10.03 | $63.6K | 0 |
| Nov 25, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 2,700 | $10.05 | $27.1K | 0 |
| Nov 14, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 1,000 | $10.00 | $10.0K | 0 |
| Nov 10, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 52,532 | $10.21 | $536.3K | 0 |
| Oct 20, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.19M | 0 |
| Sep 5, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 56,471 | $177.81 | $10.04M | 0 |
| Sep 3, 2025 | Forminard Elizabeth | Executive VP, General Counsel | Sell | 9,570 | $177.20 | $1.70M | 0 |
| Aug 25, 2025 | Duato Joaquin | CEO and Chairman of the Board | Sell | 125,824 | $179.21 | $22.55M | 0 |
| Aug 18, 2025 | Wolk Joseph J | Exec VP, CFO | Sell | 16,820 | $176.91 | $2.98M | 0 |
| Jul 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3.13M | 0 |
| Feb 26, 2025 | Decker Robert J | VP Corporate Controller | Sell | 6,999 | $165.88 | $1.16M | 0 |
| Feb 18, 2025 | Decker Robert J | VP Corporate Controller | Sell | 824 | $156.46 | $128.9K | 0 |
| Feb 18, 2025 | Forminard Elizabeth | Executive VP, General Counsel | Sell | 1,253 | $156.32 | $195.9K | 0 |
| Feb 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 385 | $156.15 | $60.1K | 0 |
| Feb 18, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 2,250 | $156.49 | $352.1K | 0 |
| Feb 18, 2025 | Swanson James D. | EVP, CIO | Sell | 1,740 | $156.54 | $272.4K | 0 |
| Feb 18, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 3,296 | $156.58 | $516.1K | 0 |
| Feb 18, 2025 | Wolk Joseph J | Exec VP, CFO | Sell | 9,080 | $156.58 | $1.42M | 0 |
| Feb 11, 2025 | Duato Joaquin | CEO and Chairman of the Board | Sell | 100,643 | $153.12 | $15.41M | 0 |
| Feb 11, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 47,436 | $153.12 | $7.26M | 0 |
| Feb 11, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 26,076 | $153.12 | $3.99M | 0 |
| Jul 27, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 20,000 | $170.32 | $3.41M | 102,696 |
| Jul 27, 2023 | Hait William | See Remarks | Sell | 14,698 | $172.00 | $2.53M | 87,747 |
| Jun 14, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 12,465 | $160.00 | $1.99M | 65,934 |
| Mar 8, 2023 | Swanson James D. | See Remarks | Sell | 1,061 | $154.66 | $164.1K | 9,215 |
| Dec 15, 2022 | Wolk Joseph J | Exec VP, CFO | Sell | 14,781 | $179.60 | $2.65M | 48,738 |
| Dec 2, 2022 | McEvoy Ashley | EVP, WW Chair, MedTech | Sell | 73,323 | $175.47 | $12.87M | 113,736-39% |
| Nov 23, 2022 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Sell | 76,923 | $176.78 | $13.60M | 126,456-38% |
JNJ Insiders
Duato Joaquin
director, officer: CEO and Chairman of the Board
Sold $135.78M
6 tradesLast: Aug 14, 2026
Similar Stocks to JNJ
LLY
Eli Lilly and Company
$1134.50-0.35%
$1.06T
ABBV
AbbVie Inc.
$261.59-0.07%
$443.43B
MRK
Merck & Co., Inc.
$143.81-0.72%
$364.55B
AMGN
Amgen Inc.
$375.65-1.54%
$211.17B
GILD
Gilead Sciences, Inc.
$145.68-0.50%
$180.84B
PFE
Pfizer Inc.
$27.46-0.94%
$158.33B
BMY
Bristol-Myers Squibb Company
$63.72-0.59%
$131.57B
BIIB
Biogen Inc.
$215.59-0.81%
$31.14B